BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS

摘要

This invention is directed to the use of one or more biomarkers defined as KRAS or NRAS gene for predicting the pharmaceutical efficacy or clinical response of MEK protein kinase inhibitor and/or Sorafenib or Regorafenib to be administred to a Hepatocellular carcinoma (HCC) patient. Futher the invention is directed to in-vitro methods for identifying mutated-type KRAS or NRAS gene in HCC patient and kits thereof.